| γ突触核蛋白与肿瘤耐药 |
| |
| 引用本文： | 陈俊毅[综述],许传亮[综述],孙颖浩[审校].γ突触核蛋白与肿瘤耐药[J].国外医学(肿瘤学分册),2010(7):507-510. |
| |
| 作者姓名： | 陈俊毅[综述] 许传亮[综述] 孙颖浩[审校] |
| |
| 作者单位： | 第二军医大学附属长海医院泌尿外科,上海200433 |
| |
| 摘 要： | γ突触核蛋白（SNCG）在许多肿瘤晚期高表达，包括乳腺癌、卵巢癌、前列腺癌、肺癌、肝癌、食管癌、直肠癌等。SNCG与BubR1相互作用损害有丝分裂检测点引起肿瘤增殖、转移和耐药。以SNCG为靶向的人工合成肽段ANK能抑制SNCG的活性，有望成为肿瘤化疗的辅助手段。
|
| 关 键 词： | 突触核蛋白类 肿瘤 药物疗法 |
Ganuna synuclein and drug resistance in cancer |
| |
| Institution: | CHEN Jun-yi, XU Chuan-liang(Department of Urology Surgery, Changhai Hospital, the Second Military Medical University, Shanghai 200433, China) |
| |
| Abstract: | Synuclein--γ （SNCG） is overexpressed in many advanced stages cancers, including breast cancer, ovarian cancer, prostate cancer, lung cancer, liver cancer, esophagus cancer, and colon cancer. SNCG stimulates the proliferation, metastasis, and drug resistance of tumor cells, through interacting with BubR1 and damage mitotic checkpoint. A peptie ANK targeted at SNCG can inhibit activity of SNCG and may be developed as an adjuvant therapy. |
| |
| Keywords: | Synucleins Neoplasms Drug therapy |
| 本文献已被 维普 等数据库收录！ |
|
